BURLINGTON, MA. (October 12, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine (“Katie”) McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period.
Ms. McClure brings more than 20 years of experience in transforming innovative medical technologies into sustainable commercial growth through strategic leadership, talent development, physician engagement, and enterprise partnerships. Ms. McClure joins Myomo from Inspire Medical Systems (“Inspire” NASDAQ:INSP), a fast-growing medical technology company for whom she was employed since 2018. During her tenure at Inspire, revenues grew from approximately $50 million to nearly $1 billion and, in the territories under her leadership, increased from $2 million to $150 million. Prior to Inspire, Ms. McClure held senior medical device sales roles at Medtronic, Tobii Dynavox and Johnson & Johnson.
“We are excited for Katie to join us as we enter our next phase of growth,” said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. “Her experience building commercial teams, expanding market access, and scaling clinical networks is directly relevant to our strategic plan.”
“My passion is in developing commercial enterprises. The MyoPro is a life-changing product for people suffering from upper-extremity impairment. I’m confident we can build a sustainable nationwide eco-system of orthotics and prosthetics providers, therapists and other healthcare professionals to expand market awareness of and access to the MyoPro,” said Ms. McClure.